-
Scandic Trust Group strengthens sales network with First Idea Consultant
-
No end to Sudan fighting despite RSF paramilitaries backing truce plan
-
US officials, NGOs cry foul as Washington snubs UN rights review
-
Injured teen medal hope Tabanelli risks missing home Winter Olympics
-
Bellingham, Foden recalled to England squad for World Cup qualifiers
-
Tanzania rights group condemns 'reprisal killings' of civilians
-
Slot urges patience as Isak returns to training with Liverpool
-
Rees-Zammit set for Wales return with bench role against Argentina
-
China's new aircraft carrier enters service in key move to modernise fleet
-
Operation Cloudburst: Dutch train for 'water bomb' floods
-
Leaders turn up the heat on fossil fuels at Amazon climate summit
-
US travel woes mount as govt shutdown prompts flight cuts
-
North Korea fires unidentified ballistic missile: Seoul military
-
West Bank's ancient olive tree a 'symbol of Palestinian endurance'
-
Global tech tensions overshadow Web Summit's AI and robots
-
Green shines as Suns thump Clippers 115-102
-
Japan to screen #MeToo film months after Oscar nomination
-
Erasmus relishing 'brutal' France re-match on Paris return
-
Rejuvenated Vlahovic taking the reins for Juve ahead of Turin derby
-
'Well-oiled' Leipzig humming along in Bayern's slipstream
-
Bangladesh cricket probes sexual harassment claims
-
NFL-best Broncos edge Raiders to win seventh in a row
-
Deadly Typhoon Kalmaegi ravages Vietnam, Philippines
-
Three killed in new US strike on alleged drug boat, toll at 70
-
Chinese microdrama creators turn to AI despite job loss concerns
-
Trump hails Central Asia's 'unbelievable potential' at summit
-
Kolya, the Ukrainian teen preparing for frontline battle
-
Big leap in quest to get to bottom of climate ice mystery
-
Markets drop as valuations and US jobs, rates spook investors
-
'Soap opera on cocaine': how vertical dramas flipped Hollywood
-
Under pressure? EU states on edge over migrant burden-sharing
-
US influencers falsely associate Mamdani with extremist group
-
Hungary's Orban to meet Trump in face of Russia oil sanctions
-
US facing travel chaos as flights cut due to govt shutdown
-
Liverpool and Man City renew rivalry as they try to narrow Arsenal gap
-
UK's Andrew asked to testify over Epstein as he formally loses titles
-
Local hero: 'DC sandwich guy' found not guilty of assaulting officer with sub
-
Dead famous: Paris puts heritage graves up for grabs
-
UK grandmother on Indonesia death row flies home
-
Former NFL star Brown extradited from Dubai to face trial in shooting - police
-
Chile presidential hopeful vows to expel 'criminal' migrants to El Salvador
-
Trump event paused in Oval Office when guest faints
-
NFL Colts add Sauce to recipe while Patriots confront Baker
-
Home owned by Miami Heat coach Spoelstra damaged by fire
-
Tesla shareholders approve Musk's $1 trillion pay package
-
World leaders launch fund to save forests, get first $5 bn
-
Villa edge Maccabi Tel Aviv in fraught Europa League match
-
Protests as Villa beat Maccabi Tel Aviv under tight security
-
US Supreme Court backs Trump admin's passport gender policy
-
Japan boss Jones backs Farrell to revive Ireland's fortunes
Drew Weissman, Nobel-winning mRNA pioneer
Drew Weissman's decades of research into mRNA technology paved the way for Covid-19 vaccines, finally earning a Nobel prize for the physician-scientist.
The 64-year-old University of Pennsylvania immunologist, who won the Nobel Medicine Prize along with long-time collaborator Katalin Kariko on Monday, is far from done.
His next quests include, among others, developing a vaccine against all future coronaviruses.
"There have been three (coronavirus) pandemics or epidemics in the past 20 years," Weissman told AFP recently, referring to the original SARS virus, MERS and Covid-19.
"You have to assume there's going to be more, and our idea was that we could wait for the next coronavirus epidemic or pandemic, and then spend a year and a half making a vaccine. Or we could make one now."
- Twin breakthroughs-
The world is now aware of the elegance of the mRNA (messenger ribonucleic acid) vaccines, that deliver genetic instructions to cells telling them to recreate the spike protein of the coronavirus, in order to trigger effective antibodies when they encounter the real thing.
But back when Weissman teamed up with Kariko in the 1990s, the research was considered a scientific dead-end, and working with DNA was considered a more promising avenue.
"We started working together in 1998, and that was without much funding and without much in the way of publications," he said.
In 2005, the pair found a way to alter synthetic RNA to stop it from causing a massive inflammatory response found in animal experiments.
"Just before our paper was published, I said 'Our phones are going to ring off the hook,'" he recalls.
"We sat there staring at our phones for five years, and they never rang!"
With a second big breakthrough in 2015, they found a new way to deliver the particles safely and effectively to their target cells, using a fatty coating called "lipid nanoparticles."
Both developments are part of the Pfizer and Moderna Covid-19 vaccines today.
- Helping people -
Weissman grew up in Lexington, Massachusetts.
His father and mother, both since retired, were an engineer and dental hygienist, respectively.
"When I was five years old, I was diagnosed as a type-one diabetic, and back then it was testing urine and taking insulin shots a few times a day," he recalled, and this motivated him to pursue science.
He was educated at Brandeis University and completed an MD-Phd program in immunology at Boston University.
As a young fellow at the National Institutes of Health, he worked for several years in Anthony Fauci's lab on HIV research, before finally arriving at his long-time home Penn.
Weissman was a practicing doctor until a few years ago, and says it brings him great joy that his invention has helped save millions of lives.
"I'm a clinician scientist, my dream since starting college and medical school was to make something that helps people. I think I can say that I've done that. So I am incredibly happy," he said.
Beyond vaccines, mRNA technology is also being heralded for its potential across medicine.
Weissman's team is working on using RNA to develop a single-injection gene therapy to overcome the defect that causes sickle cell anemia, a genetic blood disease that 200,000 babies are born with in Africa every year.
Significant technical challenges remain to ensure the treatment is able to correctly edit genes and is safe, but the researchers are hopeful.
Bone marrow transplant, an expensive treatment with serious risks, is currently the only cure.
G.AbuHamad--SF-PST